THORACIC RADIATION-THERAPY AND ADRIAMYCIN-CISPLATIN-CONTAINING CHEMOTHERAPY FOR LOCALLY ADVANCED NON-SMALL-CELL LUNG-CANCER

  • 1 January 1981
    • journal article
    • research article
    • Vol. 4  (4) , 381-388
Abstract
A total of 109 with limited-stage unresectable non-small-cell lung cancer were treated with adriamycin-cisplatin-based combination chemotherapy and thoracic irradiation. Of this number, 73 received chemotherapy (1 course) prior to irradiation; 37% (27/73) had tumor regression following chemotherapy alone. Sixty-eight percent of patients (73/107) experienced tumor regression following combined chemotherapy and irradiation. Age > 65 yr, a malignant ipsilateral pleural effusion and no response to chemotherapy alone were all strong negative prognostic factors. Three year survivals were as follows: all 109 patients, 14.0%; 89 patients without malignant pleural effusion, 17.0%; 71 patients with neither a malignant pleural efusion nor malignant ipsilateral supraclavicular adenopathy, 23.1%.

This publication has 0 references indexed in Scilit: